Rebagit pills 100mg, 90pcs

Composition

>of 1 tab. contains: Active ingredients:   rebamipid – 100 mg; Excipients: mannitol-35.7 mg, croscarmellose sodium-14 mg, pregelatinized starch-80.7 mg, sodium lauryl sulfate-2 mg, citric acid-2.3 mg, purified talc-3.1 mg, magnesium stearate-2.2 mg.

Composition of the film shell:

hypromellose-2.77 mg,

purified talc-0.57 mg,

titanium dioxide-1.11 mg,

propylene glycol-0.55 mg

Pharmacological action

Pharmacotherapy group

Gastroprotective agent

ATX code

A02BX

Pharmacodynamics :

Rebamipid increases the content of prostaglandin E2 (PGE2) in the gastric mucosa and increases the content of PGE2 and GI2 in the contents of gastric juice.

It has a cytoprotective effect on the gastric mucosa under the damaging effects of ethanol, acids and alkalis of acetylsalicylic acid.

Promotes the activation of enzymes that accelerate the biosynthesis of high-molecular glycoproteins and increases the content of mucus on the surface of the stomach wall.

Improves blood supply to the gastric mucosa activates its barrier function activates alkaline gastric secretion increases proliferation and metabolism of gastric epithelial cells cleanses the mucosa of hydroxyl radicals and suppresses superoxides produced by polymorphonuclear leukocytes and neutrophils in the presence of Helicobacter pylori protects the gastric mucosa from bacterial damage has a gastroprotective effect when exposed to the mucosa with nonsteroidal anti inflammatory drugs (NSAIDs).

Pharmacokinetics:

Absorption by mouth is high. After taking a dose of 100 mg, the peak concentration in blood plasma (Cmax) is reached in approximately 2 hours and is 340 ng / ml. The elimination half-life (T1 / 2) is approximately 10 hours. Repeated doses of the drug do not lead to its accumulation in the body. Approximately 10% of the drug is excreted mainly unchanged by the kidneys. When taken at a dose of 600 mg, traces of the hydroxylated metabolite can be isolated.

In vitro experiments have shown that from 984% to 986% of the drug binds to plasma proteins.

Indications

• gastric ulcer;
• chronic gastritis with increased acid-forming function of the stomach in the acute phase, erosive gastritis;
• prevention of mucosal damage during NSAID use.

It can be used in combination therapy.

Contraindications

• individual intolerance to ribamipid or other components of the drug;
• pregnancy;
• lactation;
• age up to 18 years.

Side effects

From the gastrointestinal tract: constipation flatulence diarrhea nausea vomiting abdominal pain impaired taste heartburn.

From the liver:  signs of liver dysfunction increased serum glutamine alanine aminotransferase (ALT) and serum glutamine aspartate aminotransferase (ACT).

From the hematopoietic system:  leukopenia granulocytopenia.

Allergic reactions:  pruritus skin rash eczematous rashes.

Other:  violation of the menstrual cycle.

Interaction

When using rebamipide as part of traditional treatment regimens for patients with Helicobacter pylori infection, the effectiveness of eradication therapy significantly increases.

Interactions with other drugs have not been studied.

How to take, course of use and dosage

Inside,1 tablet 3 times a day, washed down with a small amount of liquid. The course of treatment is 2-4 weeks, if necessary, it can be extended to 8 weeks.

The drug does not have any special effects when taken for the first time or when it is canceled.

If you miss taking one dose, you should take the next dose of the drug at the set time, do not take twice the dose of the drug.

Overdose

The symptoms of rebamipide overdose have not been described, and no cases of deliberate overdose have been reported to date. Nausea, vomiting, abdominal pain, diarrhea or constipation, and headache may occur.

Treatment:  the specific antidote is unknown. In case of overdose, the stomach should be washed and symptomatic therapy should be performed.

Functional features

Suction and distribution

After use at a dose of 100 mg_{, cmax} is reached in approximately 2 hours and is 340 ng / ml. Repeated doses of the drug do not lead to its accumulation in the body.

In vitro experiments have shown that 98.4% to 98.6% of the drug binds to plasma proteins.

Metabolism and elimination

T_1/2 is approximately 1.0 h. Approximately 10% of the drug is excreted by the kidneys, mainly in unchanged form. When taken at a dose of 600 mg, traces of the hydroxylated metabolite can be isolated.

Special instructions

Influence on the ability to drive vehicles and mechanisms

The effect of the drug on the speed of psychomotor reactions and / or the ability to drive vehicles or mechanisms has not been studied. In the case of taking the drug, you should be careful about driving a car and other activities that require increased concentration of attention.

Storage conditions

The drug should be stored out of the reach of children, dry, protected from light, at a temperature not exceeding 25°C.

Shelf

life is 2 years.

Active ingredient

Rebamipid

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults as directed by your doctor

Indications

Gastric and duodenal ulcers, Gastritis, Heartburn